Pharmacokinetics in individualizing therapy
Plavsić, F.; Francetić, I.
Srpski Arhiv Za Celokupno Lekarstvo 109(3): 391-402
1981
ISSN/ISBN: 0370-8179 PMID: 7345596 Document Number: 174471
Document emailed within 1 workday
Related Documents
Turja, J.; Grothey, A. 2008: Individualizing therapy for metastatic colorectal cancer Oncology 22(13): 1479-1481Wu, J.Z. 1986: Rational phenytoin therapy: a method for individualizing dosage Zhonghua Yi Xue Za Zhi 66(3): 134-136; 188
Calne, D.B.; Duvoisin, R.C.; Koller, W.C. 1994: Individualizing therapy in patients with disabling Parkinson's disease symptoms Neurology 44(3 Suppl 1: S8-11
Edmonds, D.; Huss, R.; Jeck, T.; Mengden, T.; Schubert, M.; Vetter, W. 1990: Individualizing antihypertensive therapy with enalapril versus atenolol: the Zurich experience Journal of Hypertension. Supplement: Official Journal of the International Society of Hypertension 8(4): S49-S52
McLeod, H.L. 2006: Individualizing cancer chemotherapy Clinical Advances in Hematology and Oncology: H&o 4(4): 259-261
Mayilvaganan, V. 2002: Steps in individualizing a standardized care plan Nursing Journal of India 93(2): 33-35
Costello, A.; Bracht, M.; Van Camp, K.; Carman, L. 1996: Parent information binder: individualizing education for parents of preterm infants Neonatal Network: Nn 15(5): 43-46
Kuritzky, L. 2015: Hot Topics in Primary Care: Individualizing Pharmacologic Management of Irritable Bowel Syndrome Journal of Family Practice 64(12 Suppl): S16-S21
Jonas, B.A.; Medeiros, B.C. 2016: Individualizing Therapeutic Strategies in Acute Myeloid Leukemia: Moving Beyond the 'One-Size-Fits-All' Approach Oncology 30(4): 330; 333
Lawlor, T.H. 2000: Individualizing treatment plan and combining approaches key to pain management and holistic care: a student's perspective Journal of the American Osteopathic Association 100(10): 609-611
Ivanov, P.L.; Zemskova, E.I.; Turakulov, R.I.; Efremov, I.A. 2005: Research of potentially linked variation of polymorphism of chromosome DNA in aspect of forensic expertise using molecular-genetic individualizing systems CD4, vWA and vWFIi Sudebno-Meditsinskaia Ekspertiza 48(2): 29-34
Bonora, M.R.; Guaglio, R.; Terzoni, P.A.; Rondanelli, R. 1980: Clinical pharmacokinetics: the pharmacological monitoring of plasmatic levels in therapy International Journal of Clinical Pharmacology Therapy and Toxicology 18(2): 73-87
Börsch, G. 1988: Old and new stomach therapy with bismuth salts. Pharmacokinetics, pharmacodynamics, toxicity Medizinische Klinik 83(18): 605-610
Fujita, M.; Koide, T.; Katayama, T.; Matsuda, H.; Yamagishi, Y.; Okuda, M.; Kataoka, Y. 2009: The pharmacokinetics and safety of oxaliplatin in a hemodialysis patient treated with mFOLFOX6 therapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(8): 1379-1382
Ciaranello, A.L.; Leroy, V.; Rusibamayila, A.; Freedberg, K.A.; Shapiro, R.; Engelsmann, B.; Lockman, S.; Kelly, K.A.; Dabis, Fçois.; Walensky, R.P. 2014: Individualizing the WHO HIV and infant feeding guidelines: optimal breastfeeding duration to maximize infant HIV-free survival Aids 28 Suppl. 3: S287-S299
Paxton, J.W. 1981: Elementary pharmacokinetics in clinical practice 4: genetic, environmental and age influences on pharmacokinetics New Zealand Medical Journal 94(697): 423-425
Brion, N.; Contrepois, A.; Carbon, C. 1983: From serum pharmacokinetics to extravascular pharmacokinetics of antibiotics. Importance of protein binding Presse Medicale 12(5): 293-296
De Mey, C.; Scharpe, S.; De Bock, R.; Bossaert, L. 1981: Predictive pharmacokinetics of amikacin using actually measured and assumed parameters, applied in 1-compartment linear pharmacokinetics Archives Internationales de Pharmacodynamie et de Therapie 253(2): 323-324
Daniel, W.; Syrek, M.; Janczar, L.; Boksa, J. 1995: The pharmacokinetics of promazine and its metabolites after acute and chronic administration to rats--a comparison with the pharmacokinetics of imipramine Polish Journal of Pharmacology 47(2): 127-136
Lu, L.I.; Wang, X.; Wang, L.; Zhang, B.; Yan, S.; Zhao, X.; Li, W.; Cui, M.; Gao, M.; Zhang, Y.; Wu, Y. 2011: Pharmacokinetics of rh-IFNalpha-2a-NGR, a tumor targeted-therapy candidate, following intramuscular administration to mice, rats and monkeys Die Pharmazie 66(9): 690-693